Polartechnics makes debut in STI diagnostics market
This article was originally published in Clinica
Executive Summary
Diagnostics company Polartechnics is breaking into the global market for sexually-transmitted infection testing, after it clinched a deal for a modified version of its CerviScreen self-sampling device. Sydney, Australia-based Polartechnics has adapted the CervicScreen, originally designed for cervical screening purposes, so that the new device collects samples to test for STIs, including chlamydia, gonorrhoea and trichomoniasis. The company will make the STI self-sampling device available in Australia through Gribbles Pathology, a pathology services provider with a network of 43 labs across the continent. The product will be distributed in China and south-east Asia through retail pharmacies. Polartechnics added that it is also currently in talks to seal distribution deals for the product in Europe and the US.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.